175 related articles for article (PubMed ID: 38047109)
1. Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.
Janicki L; Patel A; Jendrzejewski J; Hellmann A
Front Endocrinol (Lausanne); 2023; 14():1273498. PubMed ID: 38047109
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
5. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis.
Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W
J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234
[TBL] [Abstract][Full Text] [Related]
6. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer.
Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC
Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
8. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
9. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
10. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?
Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Lee SH; Song BJ; Jung SS; Bae JS
Int J Clin Oncol; 2015 Jun; 20(3):463-73. PubMed ID: 25312294
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
[TBL] [Abstract][Full Text] [Related]
12. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series.
Pessôa-Pereira D; Medeiros MFDS; Lima VMS; Silva JCD; Cerqueira TLO; Silva ICD; Fonseca LE; Sampaio LJL; Lima CRA; Ramos HE
Arch Endocrinol Metab; 2019; 63(2):97-106. PubMed ID: 30916170
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
[TBL] [Abstract][Full Text] [Related]
14. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
16. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
17. Hashimoto's Thyroiditis: A "Double-Edged Sword" in Thyroid Carcinoma.
Xu J; Ding K; Mu L; Huang J; Ye F; Peng Y; Guo C; Ren C
Front Endocrinol (Lausanne); 2022; 13():801925. PubMed ID: 35282434
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the effect of Hashimoto's thyroiditis on the diagnostic efficacy of preoperative ultrasonography on cervical lymph node lesions in papillary thyroid cancer.
Tan HL; Nyarko A; Duan SL; Zhao YX; Chen P; He Q; Zhang ZJ; Chang S; Huang P
Front Endocrinol (Lausanne); 2022; 13():987906. PubMed ID: 36714580
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
20. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
